title: HPV16/18 E5, a promising candidate for cervical cancer vaccines, affects             SCPs, cell proliferation and cell cycle, and forms a potential network with E6             and E7.
abstract: The spindle checkpoint proteins (SCPs), which sense the existence of misaligned             sister chromatids during mitosis and meiosis, are essential for cell proliferation             and differentiation. Therefore, the role of SCPs in carcinogenesis is gaining             increased attention. In this study, we analysed the expression of Bub1 and Mad2             in clinical samples by immunohistochemistry (IHC) during the development of cervical             cancer (CC), and we explored the interaction of Bub1/Mad2 with different proteins             through immunoprecipitation (IP). Furthermore, we analysed the characteristics             of four different cell models of human papillomavirus (HPV)16/18 E5. We demonstrated             that with the progression of CC, the expression of Bub1 and Mad2 was gradually             reduced under the influence of HPVE5. Overexpression of HPV16/18 E5 significantly             increased cell proliferation, as well as the percentage of cells in the S phase.             In addition, the levels of p21, Bub1 and Mad2 were markedly decreased in E5-expressing             cells. Therefore, HPV16/18 E5 plays a critical role in carcinogenesis and is a             potential therapeutic target in CC treatment.
authors.affiliation: Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, PR China.
authors.forename: Shujie
authors.initials: S
authors.lastname: Liao
authors.forename: Dongrui
authors.initials: D
authors.lastname: Deng
authors.forename: Xiaoji
authors.initials: X
authors.lastname: Hu
authors.forename: Wei
authors.initials: W
authors.lastname: Wang
authors.forename: Li
authors.initials: L
authors.lastname: Li
authors.forename: Wei
authors.initials: W
authors.lastname: Li
authors.forename: Jianfeng
authors.initials: J
authors.lastname: Zhou
authors.forename: Gang
authors.initials: G
authors.lastname: Xu
authors.forename: Li
authors.initials: L
authors.lastname: Meng
authors.forename: Shixuan
authors.initials: S
authors.lastname: Wang
authors.forename: Ding
authors.initials: D
authors.lastname: Ma
mesh_terms: D000328:Adult; D000368:Aged; D002135:Calcium-Binding Proteins / Q000235:genetics / Q000378:metabolism; D019496:Cancer Vaccines / Q000235:genetics*; D002453:Cell Cycle; D018797:Cell Cycle Proteins / Q000235:genetics / Q000378:metabolism; D002454:Cell Differentiation; D049109:Cell Proliferation; D004268:DNA-Binding Proteins / Q000235:genetics / Q000378:metabolism; D005260:Female; D006367:HeLa Cells; D052162:Human papillomavirus 16 / Q000235:genetics / Q000276:immunology*; D052161:Human papillomavirus 18 / Q000235:genetics / Q000276:immunology*; D006801:Humans; D047468:Immunoprecipitation; D064246:Mad2 Proteins; D008875:Middle Aged; D009856:Oncogene Proteins, Viral / Q000235:genetics* / Q000378:metabolism; D050725:Papillomavirus E7 Proteins / Q000235:genetics / Q000378:metabolism; D060066:Protein Interaction Maps; D017346:Protein Serine-Threonine Kinases / Q000235:genetics / Q000378:metabolism; D012097:Repressor Proteins / Q000235:genetics / Q000378:metabolism; D002583:Uterine Cervical Neoplasms / Q000235:genetics / Q000517:prevention & control / Q000821:virology*; D055815:Young Adult; D000086082:Viroporin Proteins
chemical_list: D002135:Calcium-Binding Proteins; D019496:Cancer Vaccines; D018797:Cell Cycle Proteins; D004268:DNA-Binding Proteins; D064246:Mad2 Proteins; D009856:Oncogene Proteins, Viral; D050725:Papillomavirus E7 Proteins; D017346:Protein Serine-Threonine Kinases; D012097:Repressor Proteins; C052633:E7 protein, Human papillomavirus type 18; C577697:MAD2L1 protein, human; C054859:oncogene protein E5, Human papillomavirus type 16; D000086082:Viroporin Proteins; C059731:oncogene protein E7, Human papillomavirus type 16; C584277:BUB1 protein, human; C090464:Bub1 spindle checkpoint protein